Clinical Trial Update: EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

View source ↗

Summary

Expanded Access Protocol update for combining lapatinib with capecitabine in metastatic breast cancer, sponsored by Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Lapatinib (Lapatinib)

Snippet

Sponsor: Novartis | Conditions: Neoplasms, Breast | Status: APPROVED_FOR_MARKETING